Harmony Biosciences Reports Q3 2026 Net Product Revenue of $268.9 Million Driven by WAKIX Growth
Harmony Biosciences (HRMY) reported third-quarter 2026 net product revenue of $268.9 million, representing a 12% year-over-year increase. This growth was primarily fueled by rising patient demand for WAKIX in the narcolepsy market, with the average patient count reaching 9,350 during the quarter. The company reiterated its full-year revenue guidance of $1 billion to $1.04 billion, marking a significant historical milestone for the firm. While net income saw a slight decrease to $48.2 million due to higher royalty expenses and milestone charges, the company maintains a strong liquidity position with over $1 billion in cash and investments. Looking forward, management highlighted positive Phase 1 data for BP-205 and provided timelines for upcoming clinical readouts, including EPX-100 top-line data expected in mid-2027.
Topics: clinical trial results guidance product performance revenue growth